Search Bar & Filters
Found 23 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are studying the safety, tolerability, and preliminary anti-tumor effects of oral GFH276 combined with cetuximab or standard chemotherapy in adults with locally advanced or metastatic RAS-mutated solid tumors and pancreatic ductal adenocarcinoma PDAC. This open-label, multicenter Phase IbII trial aims to find the best dose for further study and evaluate treatment outcomes in this patient group. Participants will be assigned to one of three treatment groups GFH276 with cetuximab given intravenously every two weeks, GFH276 with nab-paclitaxel plus gemcitabine on cycles of three or four weeks, or GFH276 with mFOLFIRINOX chemotherapy given every two weeks. The Phase Ib stage involves increasing GFH276 doses to identify dose-limiting toxicities and safety, followed by Phase II expansion to assess anti-tumor effectiveness and long-term safety of each combination. During the study, participants will undergo tumor imaging, laboratory tests, adverse event monitoring, and blood sampling to study drug levels. Treatment continues until disease worsens, unacceptable side effects occur, consent is withdrawn, or the study ends. Safety and response will be followed for up to 24 months, with detailed assessments of adverse events, tumor response, and pharmacokinetics included.
Actively Recruiting
Heart attacks occur when a blood clot blocks the hearts blood vessels, stopping blood flow to the heart muscle. This trial focuses on patients with ST-elevation myocardial infarction STEMI and looks at how microcirculatory damage can be measured using the Index of Microcirculatory Resistance IMR. The study aims to find out if treating patients with impaired microcirculatory perfusion using low-dose intracoronary thrombolytic therapy can reduce heart muscle damage and improve clinical outcomes. Participants who have had a heart attack and undergone angioplasty will have their IMR measured. Those with an IMR above 32 will be randomly assigned to receive either low-dose tenecteplase a clot-dissolving drug or a placebo sterile water administered directly into the coronary artery. Patients with lower IMR will be followed in a registry. The treatment is given as an intracoronary infusion over 3 minutes. Cardiac enzymes, MRI scans, and other heart function tests will be done at various time points. During the study, participants will have heart enzyme tests at hospital admission and discharge. Those in the randomised group will receive cardiac MRI scans at discharge and six months later. Follow-up visits will occur at 30 days, then 6, 12, and 24 months after discharge to monitor heart function, rehospitalisation, and mortality. The main outcomes measured include cardiovascular death, heart failure rehospitalisation, heart attack size, and bleeding events, with safety and efficacy monitored closely throughout the study period.
Actively Recruiting
Researchers are evaluating the drug BAY 3713372 to treat solid tumors that have a specific genetic deletion called MTAP deletion. This first-in-human study aims to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with these tumors. The study focuses on measuring side effects, toxicities, drug levels in the blood, and participants responses to treatment as well as how long their cancer remains stable. Participants will receive BAY 3713372 taken by mouth daily. The study has two parts a dose escalation phase where different groups receive increasing doses of the drug alone to find a safe and effective dose, followed by a dose expansion phase where more participants receive BAY 3713372 alone or combined with other treatments based on the dose found. Some groups focus on specific tumor types, including non-small cell lung cancer, pancreatic cancer, and glioblastoma. Participants will visit the study site at least twice before treatment starts and multiple times during treatment. After treatment ends, they will have follow-up visits every 9 weeks until their cancer worsens or they stop the study. Throughout the trial, health assessments include blood and urine tests, heart monitoring with electrocardiograms, scans like CT or MRI to check cancer status, and tumor sample collection. The research team will also contact participants every 3 months for up to 2 years after their last dose to monitor health and safety.
Actively Recruiting
Crohns disease is a long-term condition causing inflammation that can affect any part of the gut. This research aims to evaluate the safety and effectiveness of TAK-279 compared to a placebo in adults with moderately to severely active Crohns disease. The main goal is to find out if three different doses of TAK-279 can reduce bowel inflammation and ulcers after 12 weeks of treatment using endoscopy to assess the bowel. Participants will be randomly assigned to receive one of three doses of TAK-279 or a placebo capsule, taken orally. The treatment period lasts for 52 weeks, or 1 year. The study includes an initial induction phase with treatment assignment and a 4-week safety follow-up phase after completing treatment. The trial is conducted at multiple centers worldwide and involves about 268 participants. Participants will visit the study clinic 15 times during the study. During these visits, researchers will conduct endoscopies and use scores like the Simple Endoscopic Score for Crohns Disease SES-CD and the Crohns Disease Activity Index CDAI to measure inflammation and disease activity. Quality of life and fatigue will also be assessed using questionnaires. Safety and tolerability will be monitored throughout the study and during the follow-up period, with total participation lasting about 60 weeks.
Actively Recruiting
Researchers are studying how well and safely elafibranor works compared to a placebo in adults with Primary Sclerosing Cholangitis PSC, a rare liver disease that causes inflammation and scarring of the bile ducts. PSC can lead to serious liver damage, potentially requiring a liver transplant or causing death. This phase III study involves about 350 participants with large duct PSC. Participants will be randomly assigned to take either elafibranor 120 mg once daily or a placebo tablet daily. The study includes a screening period, a treatment period expected to last about 5 years until enough health events occur, and a post-treatment safety follow-up lasting around four weeks. The study is double-blind, meaning neither participants nor researchers know which treatment is given. Throughout the study, participants will have routine clinical assessments, lab tests, imaging evaluations, and patient-reported assessments to monitor disease progression, symptoms like pruritus and fatigue, quality of life, and safety. Researchers will measure event-free survival and monitor for adverse events and changes in vital signs and lab parameters. Participants may withdraw anytime, and the total study duration may extend over several years.
Actively Recruiting
Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.
Actively Recruiting
Researchers are investigating treatments for participants with unresectable stage III Non-small Cell Lung Cancer NSCLC who have completed platinum-based concurrent chemoradiation therapy without disease progression. This Phase 3 randomized study compares the effects of two drugs, Pumitamig and Durvalumab, to evaluate their impact on progression-free survival and other clinical outcomes over several years. The trial is sponsored by Bristol-Myers Squibb and aims to better understand treatment options after initial chemoradiation. Participants are randomly assigned to receive either Pumitamig or Durvalumab monotherapy, each given at specified doses on specified days. The study treatment follows completion of concurrent chemoradiotherapy, with no masking or placebo involved. The trial includes an observation period lasting up to three years for primary outcome measures and extends up to approximately nine years for overall survival monitoring. During the study, participants will undergo regular assessments to monitor progression-free survival based on standardized imaging criteria, along with evaluations of overall survival, response rates, disease control, and treatment duration. These assessments are conducted by blinded independent reviewers and investigators. Participants will be monitored closely for safety and treatment effects throughout the trial, which spans several years from enrollment through long-term follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.
1-10 of 23
1